Moberg Pharma Zukünftiges Wachstum
Future Kriterienprüfungen 5/6
Für Moberg Pharma wird ein Gewinn- und Umsatzwachstum von 100.9% bzw. 63.3% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 100.9% pro Jahr steigen soll.
Wichtige Informationen
100.9%
Wachstumsrate der Gewinne
100.90%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 36.7% |
| Wachstumsrate der Einnahmen | 63.3% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 13 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • Apr 21
MOB: Dual Terbinafine Suppliers And Broader Mandate Will Support Future Re Rating Potential
Analysts now hold the fair value estimate for Moberg Pharma steady at SEK 13.0, reflecting unchanged assumptions on discount rate, revenue growth, profit margin and future P/E, and indicating that the recent review has not altered their SEK-based price target framework. What's in the News Moberg Pharma plans to propose an amendment to its articles of association at the AGM scheduled for 21 May 2026.Narrativ-Update • Apr 06
MOB: Dual Terbinafine Sourcing Will Support Future Re Rating Potential
Analysts have reaffirmed their price target for Moberg Pharma at SEK 13.0 per share, citing unchanged views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Regulators have approved an additional supplier of terbinafine for MOB-015, Moberg Pharma's drug for nail fungus, after a process that started in April 2024 (Key Developments).Narrativ-Update • Mar 23
MOB: Dual Supplier Approval Will Support Future Re Rating Potential
Analysts have maintained their SEK fair value estimate for Moberg Pharma at SEK 13.0, with unchanged assumptions for the discount rate, revenue growth, profit margin and future P/E. This suggests their view on the company’s risk and earnings outlook remains essentially intact.Narrativ-Update • Mar 07
MOB: Stable Assumptions And Profitability Outlook Will Support Future Re Rating
Analysts have maintained their SEK 13.0 price target for Moberg Pharma, reflecting unchanged views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. Valuation Changes Fair Value: SEK 13.0 is unchanged, with only rounding differences between the previous SEK 13 and the current SEK 13.0 figure.Narrativ-Update • Feb 21
MOB: Higher Profitability Assumptions Will Support Re Rating Of Undervalued Shares
Analysts have adjusted their price target on Moberg Pharma to SEK 13.0. This reflects updated views on revenue growth, profit margin and a lower future P/E assumption. Valuation Changes Fair Value: SEK 13.0 is unchanged, indicating no revision to the overall price estimate.Narrativ-Update • Feb 05
MOB: Undervalued Shares Will Rely On Stable Assumptions To Re-Rate
Analysts have kept their price target for Moberg Pharma steady at SEK 13.00. This reflects unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E.Narrativ-Update • Jan 22
MOB: Europe Licensing Agreement Will Support Future Share Price Upside
Analysts have kept their price target for Moberg Pharma steady at SEK 13.0. This reflects unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E despite the latest review of their model inputs. What's in the News Karo Healthcare AB and Moberg Pharma AB have signed an exclusive licensing agreement for the commercialisation of MOB-015 in 19 European markets, covering a population of about 500 million people (Key Developments).Narrativ-Update • Jan 08
MOB: Europe Licensing Agreement Will Support Strong Future Share Price Upside
Analysts have maintained their price target on Moberg Pharma at SEK 13.0, with unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. This indicates their core view on the stock remains intact for now.Narrativ-Update • Dec 16
MOB: Exclusive European Licensing Deal Will Drive Strong Future Share Upside
Analysts have marginally adjusted their price target on Moberg Pharma, reiterating a fair value of SEK 13.0 per share as they maintain their assumptions for discount rate, revenue growth, profit margins, and future valuation multiples. What's in the News Karo Healthcare AB signs an exclusive licensing agreement with Moberg Pharma for the commercialisation of MOB-015 across 19 European markets, including all major EU countries and the United Kingdom, ensuring a coordinated launch under the Lamisil brand (Company announcement) The licensing deal grants Karo responsibility for marketing, distribution, and sales in 11 countries where MOB-015 is already approved but not yet launched, accelerating the product’s European rollout (Company announcement) MOB-015, a new topical terbinafine formulation, demonstrates mycological cure rates of 76 percent in registration studies, delivering efficacy on par with oral treatment and addressing historical challenges in penetrating the nail (Company announcement) The agreement provides Moberg Pharma with access to a total addressable population of about 500 million people in Europe, significantly expanding the commercial potential of MOB-015 (Company announcement) Valuation Changes Fair Value: Unchanged at SEK 13.0 per share, reflecting a stable outlook for Moberg Pharma’s intrinsic valuation.Narrativ-Update • Dec 02
MOB: Exclusive Licensing Deal Will Unlock Major European Market Launches
Analysts have maintained their price target for Moberg Pharma at SEK 13.00. This reflects continued confidence in the company's earnings outlook and growth potential.Narrativ-Update • Nov 18
MOB: Licensing Agreement Will Drive Expansion Across Europe This Year
Analysts have raised their price target for Moberg Pharma from SEK 11 to SEK 13. This change reflects updated forecasts that consider notable shifts in anticipated revenue growth, profitability, and market conditions.Analyseartikel • Nov 07
We're Not Worried About Moberg Pharma's (STO:MOB) Cash Burn
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analyseartikel • May 16
Shareholders Will Probably Hold Off On Increasing Moberg Pharma AB (publ)'s (STO:MOB) CEO Compensation For The Time Being
Key Insights Moberg Pharma's Annual General Meeting to take place on 22nd of May Total pay for CEO Anna Ljung includes...
Neues Narrativ • Apr 13
Norway Expansion And EU Approvals Will Strengthen Future Position
Expansion in Norway and obtaining EU approvals bolster revenue potential and support Moberg Pharma's European growth strategy.Analyseartikel • Feb 12
Companies Like Moberg Pharma (STO:MOB) Can Afford To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyseartikel • Sep 14
We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analyseartikel • May 08
Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year
Key Insights Moberg Pharma to hold its Annual General Meeting on 14th of May Salary of kr1.99m is part of CEO Anna...Analyseartikel • Nov 16
Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyseartikel • Jan 17
Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Analyseartikel • Dec 03
Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 95 | 27 | N/A | 34 | 1 |
| 12/31/2027 | 56 | 9 | N/A | 15 | 1 |
| 12/31/2026 | 23 | -18 | N/A | -16 | 1 |
| 3/31/2026 | 15 | -26 | -45 | -12 | N/A |
| 12/31/2025 | 14 | -27 | -61 | -17 | N/A |
| 9/30/2025 | 12 | -258 | -71 | -16 | N/A |
| 6/30/2025 | 12 | -255 | -80 | -14 | N/A |
| 3/31/2025 | 13 | -251 | -92 | -21 | N/A |
| 12/31/2024 | 10 | -255 | -90 | -16 | N/A |
| 9/30/2024 | 9 | -18 | -115 | -27 | N/A |
| 6/30/2024 | 5 | -23 | -134 | -33 | N/A |
| 3/31/2024 | 1 | -23 | -139 | -31 | N/A |
| 12/31/2023 | N/A | -21 | -157 | -33 | N/A |
| 9/30/2023 | N/A | -18 | -134 | -29 | N/A |
| 6/30/2023 | 0 | -16 | -105 | -21 | N/A |
| 3/31/2023 | 0 | -16 | -96 | -16 | N/A |
| 12/31/2022 | 0 | -16 | -85 | -17 | N/A |
| 9/30/2022 | 0 | -17 | -75 | -14 | N/A |
| 6/30/2022 | N/A | -16 | -70 | -12 | N/A |
| 3/31/2022 | N/A | -16 | -56 | -7 | N/A |
| 12/31/2021 | N/A | -16 | -47 | -15 | N/A |
| 9/30/2021 | 34 | 8 | -44 | -9 | N/A |
| 6/30/2021 | 34 | 7 | -46 | -12 | N/A |
| 3/31/2021 | 34 | 5 | -58 | -16 | N/A |
| 12/31/2020 | 34 | 7 | -52 | -10 | N/A |
| 6/30/2020 | 50 | 20 | -47 | 4 | N/A |
| 6/30/2019 | 31 | -8 | N/A | -76 | N/A |
| 3/31/2019 | 455 | 31 | N/A | 88 | N/A |
| 12/31/2018 | 5 | -28 | N/A | 74 | N/A |
| 9/30/2018 | 341 | 9 | N/A | 87 | N/A |
| 6/30/2018 | 340 | 19 | N/A | 109 | N/A |
| 3/31/2018 | 334 | 6 | N/A | 68 | N/A |
| 12/31/2017 | 439 | 11 | N/A | 54 | N/A |
| 9/30/2017 | 438 | -1 | N/A | 30 | N/A |
| 6/30/2017 | 434 | 0 | N/A | -44 | N/A |
| 3/31/2017 | 369 | 35 | N/A | -17 | N/A |
| 12/31/2016 | 334 | 33 | N/A | -18 | N/A |
| 9/30/2016 | 299 | 36 | N/A | -21 | N/A |
| 6/30/2016 | 261 | 32 | N/A | 12 | N/A |
| 3/31/2016 | 282 | 9 | N/A | 32 | N/A |
| 12/31/2015 | 286 | 26 | N/A | 31 | N/A |
| 9/30/2015 | 276 | 25 | N/A | 34 | N/A |
| 6/30/2015 | 260 | 20 | N/A | 30 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: MOB wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2%).
Ertrag vs. Markt: MOB wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: MOB wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: MOBDie Einnahmen des Unternehmens (63.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (0.04% pro Jahr).
Hohe Wachstumseinnahmen: MOBDie Einnahmen des Unternehmens (63.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von MOB in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/24 16:53 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Moberg Pharma AB (publ) wird von 4 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Bjorn Rydell | ABG Sundal Collier Sponsored |
| Klas Pyk | Nordea Markets |
| Mats Hyttinge | Redeye |